Literature DB >> 27620368

Dual antiplatelet therapy duration after drug-eluting stents: how long?

Gérard Helft1.   

Abstract

Year:  2016        PMID： 27620368      PMCID： PMC4999771          DOI： 10.21037/jtd.2016.07.45

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  19 in total

1.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

Authors:  Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting
Journal:  Circulation       Date:  2011-11-07       Impact factor: 29.690

2.  Stent thrombosis in randomized clinical trials of drug-eluting stents.

Authors:  Laura Mauri; Wen-hua Hsieh; Joseph M Massaro; Kalon K L Ho; Ralph D'Agostino; Donald E Cutlip
Journal:  N Engl J Med       Date:  2007-02-12       Impact factor: 91.245

3.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

Authors:  Fausto Feres; Ricardo A Costa; Alexandre Abizaid; Martin B Leon; J Antônio Marin-Neto; Roberto V Botelho; Spencer B King; Manuela Negoita; Minglei Liu; J Eduardo T de Paula; José A Mangione; George X Meireles; Hélio J Castello; Eduardo L Nicolela; Marco A Perin; Fernando S Devito; André Labrunie; Décio Salvadori; Marcos Gusmão; Rodolfo Staico; J Ribamar Costa; Juliana P de Castro; Andrea S Abizaid; Deepak L Bhatt
Journal:  JAMA       Date:  2013-12-18       Impact factor: 56.272

4.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).

Authors:  Byeong-Keuk Kim; Myeong-Ki Hong; Dong-Ho Shin; Chung-Mo Nam; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Tae-Soo Kang; Byoung-Eun Park; Woong-Chol Kang; Seung-Hwan Lee; Jung-Han Yoon; Bum-Kee Hong; Hyuck-Moon Kwon; Yangsoo Jang
Journal:  J Am Coll Cardiol       Date:  2012-09-19       Impact factor: 24.094

5.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

Review 6.  Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis.

Authors:  Tullio Palmerini; Diego Sangiorgi; Marco Valgimigli; Giuseppe Biondi-Zoccai; Fausto Feres; Alexandre Abizaid; Ricardo A Costa; Myeong-Ki Hong; Byeong-Keuk Kim; Yangsoo Jang; Hyo-Soo Kim; Kyung Woo Park; Andrea Mariani; Diego Della Riva; Philippe Genereux; Martin B Leon; Deepak L Bhatt; Umberto Bendetto; Claudio Rapezzi; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2015-03-24       Impact factor: 24.094

Review 7.  Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis.

Authors:  Sammy Elmariah; Laura Mauri; Gheorghe Doros; Benjamin Z Galper; Kelly E O'Neill; Philippe Gabriel Steg; Dean J Kereiakes; Robert W Yeh
Journal:  Lancet       Date:  2014-11-16       Impact factor: 79.321

8.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.

Authors:  Gregg W Stone; Jeffrey W Moses; Stephen G Ellis; Joachim Schofer; Keith D Dawkins; Marie-Claude Morice; Antonio Colombo; Erick Schampaert; Eberhard Grube; Ajay J Kirtane; Donald E Cutlip; Martin Fahy; Stuart J Pocock; Roxana Mehran; Martin B Leon
Journal:  N Engl J Med       Date:  2007-02-12       Impact factor: 91.245

9.  Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial.

Authors:  Gérard Helft; Philippe Gabriel Steg; Claude Le Feuvre; Jean-Louis Georges; Didier Carrie; Xavier Dreyfus; Alain Furber; Florence Leclercq; Hélène Eltchaninoff; Jean-François Falquier; Patrick Henry; Simon Cattan; Laurent Sebagh; Pierre-Louis Michel; Albert Tuambilangana; Nadjib Hammoudi; Franck Boccara; Guillaume Cayla; Hervé Douard; Abdourahmane Diallo; Emmanuel Berman; Michel Komajda; Jean-Philippe Metzger; Eric Vicaut
Journal:  Eur Heart J       Date:  2015-09-12       Impact factor: 29.983

Review 10.  Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  John A Bittl; Usman Baber; Steven M Bradley; Duminda N Wijeysundera
Journal:  J Am Coll Cardiol       Date:  2016-03-29       Impact factor: 24.094
View more
  2 in total

1.  New guidelines on duration of dual antiplatelet therapy in patients with coronary artery disease: what's the novelty?

Authors:  Gérard Helft
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

2.  Endothelium-Mimicking Multifunctional Coating Modified Cardiovascular Stents via a Stepwise Metal-Catechol-(Amine) Surface Engineering Strategy.

Authors:  Ying Yang; Peng Gao; Juan Wang; Qiufen Tu; Long Bai; Kaiqin Xiong; Hua Qiu; Xin Zhao; Manfred F Maitz; Huaiyu Wang; Xiangyang Li; Qiang Zhao; Yin Xiao; Nan Huang; Zhilu Yang
Journal:  Research (Wash D C)       Date:  2020-04-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.